Tuis532523 ⢠BOM
add
Biocon Ltd
Vorige sluiting
ā¹318,80
Dagwisseling
ā¹317,00 - ā¹325,15
Jaarwisseling
ā¹270,00 - ā¹404,60
Markkapitalisasie
385,48Ā mjd INR
Gemiddelde volume
102,39Ā k
P/V-verhouding
47,85
Dividend-opbrengs
0,16%
PrimĆŖre beurs
NSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(INR) | Des. 2024info | J/J-verandering |
---|---|---|
Inkomste | 38,21Ā mjd | -3,35% |
Bedryfskoste | 21,36Ā mjd | -3,34% |
Netto inkomste | 251,00Ā m | -96,20% |
Netto winsgrens | 0,66 | -96,05% |
Wins per aandeel | 0,13 | -97,54% |
EBITDA | 7,07Ā mjd | -9,98% |
Effektiewe belastingkoers | 47,98% | ā |
Balansstaat
Totale bates
Totale aanspreeklikheid
(INR) | Des. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 26,50Ā mjd | -30,00% |
Totale bates | ā | ā |
Totale aanspreeklikheid | ā | ā |
Totale ekwiteit | 267,20Ā mjd | ā |
Uitstaande aandele | 1,20Ā mjd | ā |
Prys om te bespreek | 1,87 | ā |
Opbrengs op bates | ā | ā |
Opbrengs op kapitaal | 1,88% | ā |
Kontantvloei
Netto kontantverandering
(INR) | Des. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 251,00Ā m | -96,20% |
Kontant van bedrywe | ā | ā |
Kontant van beleggings | ā | ā |
Kontant van finansiering | ā | ā |
Netto kontantverandering | ā | ā |
Beskikbare kontantvloei | ā | ā |
Meer oor
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Gestig
1978
Hoofkwartier
Webwerf
Werknemers
16Ā 315